Search

Norvedan (2-phenyl-4-p-chlorophenyl-thiazole-5-ylacetic acid) has been investigated for anti-inflammatory activity using an 'adjuvant arthirits' in rats and for analgesic activity using a writhing test in mice and a pressure test in rats. At oral doses of 10, 30 and 100 mg/kg Norvedan caused a dose-related inhibition of the primary swelling of the paw injected with adjuvant and the development of secondary lesions was also inhibited. Writhing induced in mice by i.p. administered acetic acid was also reduced by Norvedan at oral doses of 30 mg/kg and above and the response was related to dose. Against pain induced in rats by application of pressure to an inflamed paw Norvedan alsp showed good activity which was present for at least 6 hr after dosing.

1-(Theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was compared with several reference compounds for effects on serum cholesterol and triglyceride levels of hypercholesterolaemic rats. ML 1024 appeared to be superior to the reference compounds in reducing cholesterol and triglyceride levels and may have a different mechanism of action to clofibrate.

Lindane was administered to male and female Beagle dogs at dietary levels of 25, 50 and 100 ppm for 104 weeks, and of 200 ppm for 32 weeks. One death at 25 ppm and one at 200 ppm were not considered to be related to the test compound. At 100 and 200 ppm, SAP levels were raised and the livers were dark, friable and slightly enlarged but without any detected histopathological change. HVSA changes, possibly indicative of non-specific neuronal irritation, were recorded in the EEG tracings at 200 but not at 100 ppm. There were no other indications of an adverse effect of lindane. The negative findings at 50 ppm are consistent with a 'no-effect level' for this species of 1.25 mg/kg body weight, comparable with for the rat, and with proposed human ADI of 0.0125 mg/kg body weight.

9alphaFluorohydrocortisone, prednisolone, and hydrocortisone promoted the growth of the human tumour (H.S.l) in weanling rats, but deoxycortone acetate was ineffective even when injected in very high dosage; Cortrophin ZN, a long-acting corticotrophin preparation, was just as effective as cortisone. This effect of corticotrophin on tumour growth was mediated by the adrenal cortex, and was related to the enhanced secretion of adrenocorticoids; some correlation existed between tumour size and adrenal hypertrophy in the corticotrophin-treated rats. The action of adrenal steroids and of corticotrophin in promoting the growth of the tumour is discussed.